Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma Chi Hang WongHerbert H. LoongAnthony T. C. Chan PRECLINICAL STUDIES 24 August 2013 Pages: 1399 - 1408
ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity Maria Ait-TihyatyZakaria RachidBertrand J. Jean-Claude PRECLINICAL STUDIES 20 August 2013 Pages: 1409 - 1423
Ketoprofen-loaded polymeric nanocapsules selectively inhibit cancer cell growth in vitro and in preclinical model of glioblastoma multiforme Elita F. da SilveiraJanaine M. ChassotElizandra Braganhol PRECLINICAL STUDIES 27 September 2013 Pages: 1424 - 1435
OM-RCA-01, a novel humanized monoclonal antibody targeting fibroblast growth factor receptor 1, in renal cell carcinoma model Ilya TsimafeyeuElina ZavelevaWalter Low PRECLINICAL STUDIES 13 September 2013 Pages: 1436 - 1443
Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360) Godefridus J. PetersKees SmidDeog Joong Kim PRECLINICAL STUDIES 19 September 2013 Pages: 1444 - 1457
Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation Ji-Young SongChoung-Soo KimJene Choi PRECLINICAL STUDIES 26 September 2013 Pages: 1458 - 1465
Chemo-sensitisation of HeLa cells to Etoposide by a Benzoxazine in the absence of DNA-PK inhibition Cheree FitzgibbonSaleh IhmaidChristopher Bradley PRECLINICAL STUDIES Open access 22 September 2013 Pages: 1466 - 1475
Bio-distribution study of Reolysin® (pelareorep) through a single intravenous infusion in Sprague-Dawley rats Romit ChakrabartyHue TranMatt Coffey PRECLINICAL STUDIES 13 October 2013 Pages: 1476 - 1486
Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study Normand BlaisD. Ross CamidgeLaura Q. Chow PHASE I STUDIES Open access 22 August 2013 Pages: 1487 - 1498
Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13) Philipp HarterJalid SehouliAndreas du Bois PHASE I STUDIES 05 September 2013 Pages: 1499 - 1504
Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer Prasanth GanesanSarina Piha-PaulApostolia M. Tsimberidou PHASE I STUDIES 28 August 2013 Pages: 1505 - 1513
A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas Seok Jin KimHye Jin KangWon Seog Kim PHASE I STUDIES 24 August 2013 Pages: 1514 - 1521
NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies S. F. DentK. A. GelmonL. Seymour PHASE I STUDIES 27 September 2013 Pages: 1522 - 1529
A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma A. HollebecqueE. DeutschJean-Charles Soria PHASE I STUDIES 28 September 2013 Pages: 1530 - 1538
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies William R. SchelmanAnne M. TraynorHoward H. Bailey PHASE I STUDIES 10 October 2013 Pages: 1539 - 1546
Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer K.-W. LeeS. R. ParkY.-J. Bang PHASE I STUDIES 04 October 2013 Pages: 1547 - 1558
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine Matthew P. GoetzHeidi A. McKeanMatthew M. Ames PHASE I STUDIES 10 October 2013 Pages: 1559 - 1567
A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site Asuka TsuyaTakayasu KurataKazuhiko Nakagawa PHASE II STUDIES 24 August 2013 Pages: 1568 - 1572
Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study M. Martin-RichardR. GallegoJ. Maurel PHASE II STUDIES 28 September 2013 Pages: 1573 - 1579
Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients Su Jin LeeJongtae LeeWon Ki Kang PHASE II STUDIES 07 September 2013 Pages: 1580 - 1586
Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer Cheryl HoAngela M. DaviesDavid R. Gandara PHASE II STUDIES 08 September 2013 Pages: 1587 - 1591
A non-comparative phase II study of dose intensive chemotherapy with doxorubicin and ifosfamide followed by high dose ICE consolidation with PBSCT in non-resectable, high grade, adult type soft tissue sarcomas Jörg Thomas HartmannM. HorgerC. Bokemeyer PHASE II STUDIES 04 October 2013 Pages: 1592 - 1601
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide Changhoon YooJeeyun LeeJin-Hee Ahn PHASE II STUDIES 14 September 2013 Pages: 1602 - 1608
Nanoparticulate paclitaxel demonstrates antitumor activity in PC3 and Ace-1 aggressive prostate cancer cell lines Sandra M. Axiak-BechtelSenthil R. KumarCharles J. Decedue SHORT REPORT 13 September 2013 Pages: 1609 - 1615
The diaryl oxazole PC-046 is a tubulin-binding agent with experimental anti-tumor efficacy in hematologic cancers Terry H. LandowskiBetty K. SamulitisRobert T. Dorr SHORT REPORT 14 September 2013 Pages: 1616 - 1625
Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO) T. ValentinC. FournierC. Chevreau SHORT REPORT 05 September 2013 Pages: 1626 - 1627
Erratum to: Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: Results of a Phase II trial Craig ReynoldsAlexander I. SpiraLina Asmar Erratum 06 July 2013 Pages: 1628 - 1628